Eli Lilly received a significant boost after UBS raised its price target to $1,250, maintaining a bullish outlook on the company's robust obesity pipeline, including the anticipated strong launch of the oral drug Orforglipron.
- The Lilly Endowment Inc. executed a large sale on January 7, 2026, offloading 293,446 shares for total proceeds of $322,380,730.
- Growth prospects are further supported by recent positive trial data and the strategic Ventyx acquisition, bolstering its position in immunology and cardiometabolic treatments.
- The stock closed at $1085.19 and remained essentially unchanged in after-hours trading at $1084.99.